Preview Mode Links will not work in preview mode

Jun 27, 2019

Investigator Perspectives on the Current and Future Management of Newly Diagnosed Ovarian Cancer — Part 1: Our most recent one-on-one interview with Dr Monk featuring emerging research and cases from his practice:

  • Guidelines for germline and somatic BRCA testing in ovarian cancer (00:00)
  • Incidence and potential impact of other clinically relevant genetic abnormalities on clinical decision-making in the front-line setting (2:52)
  • Patient selection for neoadjuvant systemic therapy in clinical practice (5:31)
  • Bevacizumab as a component of neoadjuvant systemic therapy for patients with ovarian cancer (7:52)
  • Clinical approach to patient selection for neoadjuvant chemotherapy; perspective on optimal schedule and dose of neoadjuvant regimen (10:47)
  • Importance of the extent of response to neoadjuvant chemotherapy in the timing of debulking surgery (13:57)
  • Therapeutic approach for patients with newly diagnosed ovarian cancer, germline BRCA mutations, bilateral pleural effusions and liver metastases (16:17)
  • Lingering controversies regarding the use of intraperitoneal chemotherapy for ovarian cancer (18:30)
  • GOG-0252: Design and results of a Phase III trial of intravenous or intraperitoneal chemotherapy, each in combination with bevacizumab, for advanced ovarian cancer (20:40)
  • Perspective on the recent FDA approval of bevacizumab in combination with carboplatin and paclitaxel followed by single-agent bevacizumab for Stage III or IV epithelial ovarian cancer after initial surgical resection (22:29)
  • Importance of disease stage and amount of residual disease in the decision to use bevacizumab as a component of primary therapy after debulking surgery (25:21)
  • Evaluating the optimal duration of maintenance bevacizumab (26:39)
  • Effect of bevacizumab on progression-free survival for patients with high-risk disease (28:19)
  • Risk of bevacizumab-associated gastrointestinal perforation; contraindications to bevacizumab (29:57)
  • Perspective on combining a PARP inhibitor with bevacizumab as maintenance therapy for patients with advanced platinum-sensitive ovarian cancer (32:15)
  • PAOLA-1: An ongoing Phase III trial of olaparib combined with bevacizumab as maintenance therapy for patients with advanced ovarian cancer after first-line platinum-based chemotherapy in combination with bevacizumab (35:42)
  • Practical approaches to mitigating carboplatin/paclitaxel-induced peripheral neuropathy (36:58)
  • Comparison of treatment-associated neurotoxicity with nab paclitaxel and solvent-based paclitaxel (39:36)
  • Clinical experience with bevacizumab for ovarian cancer; management of hypertension and proteinuria (41:08)
  • Activity and ongoing investigation of anti-angiogenic agents alone or in combination with PARP inhibitors for advanced ovarian cancer (42:46)
  • FDA breakthrough therapy designation for lenvatinib in combination with pembrolizumab for previously treated advanced microsatellite instability (MSI)-nonhigh/mismatch repair proficient endometrial cancer (44:14)
  • Rationale for the design of ongoing studies combining immune checkpoint inhibitors with anti-angiogenic agents and/or PARP inhibitors (45:47)
  • Modulation of gut microbiome to enhance response to anti-PD-1 immunotherapy; impact of antibiotics on response to treatment with immune checkpoint inhibitors (49:00)

Select publications